Our generous Partners and Supporters, listed below, help OptumHealth provide educational opportunities throughout the year for the payer community and medical professionals who manage patients with complex and chronic medical conditions.

OptumHealth would like to thank the organizations that have joined the annual "Partner and Supporter" program. Their ongoing support demonstrates their commitment to the education of managed care organizations, nurses, physicians and other health care professionals regarding the many issues surrounding complex medical conditions.

Annual Partners and Supporters

Platinum

Amgen, the world's leading biotechnology company, discovers, develops, manufactures and delivers important human therapeutics based on advances in cellular and molecular biology including EPOGENİ (Epoetin alfa), Aranespİ (darbepoetin alfa), NEUPOGENİ (Filgrastim), Neulastaİ (pegfilgrastim), Enbrelİ (etanercept), Sensiparİ (cinacalcet HCl) and Kepivance^TM (palifermin). Amgen's dedication to scientific excellence is driven by our mission to serve patients.

Boehringer Ingelheim Pharmaceuticals, Inc., the US subsidiary of Boehringer Ingelheim, headquartered in Germany, operates globally in 45 countries with nearly 36,000 employees. The company is committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

Gold

Cephalon Oncology is committed to enhancing the lives of cancer patients through the discovery, development and commercialization of innovative medicines, providing therapeutic solutions enhancing the quality and length of life. Cephalon Oncology has an extensive portfolio of products in hematology, solid tumors and supportive care. For information visit www.CephalonOncology.com.

Eisai Inc. is a U.S. pharmaceutical subsidiary of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world.  Eisai focuses its efforts in three therapeutic areas: neurology, gastrointestinal disorders and oncology/critical care.  Established in 1995 and ranked among the top-20 U.S. pharmaceutical companies (based on retail sales), Eisai Inc. began marketing its first product in the United States in 1997 and has rapidly grown to become an integrated pharmaceutical business with fiscal year 2007 (year ended March 31, 2008) sales of approximately $3 billion, including the results of the acquisition of MGI PHARMA, Inc.   Eisai Inc. employs approximately 1,500 people at its headquarters in Woodcliff Lake, NJ, at its state-of-the-art pharmaceutical production and formulation research and development facility in Research Triangle Park, NC, and in the field.  For more information about Eisai, please visit www.eisai.com.

Novartis Pharmaceutical Corporation marks its 20th year as the leading contributor to transplant science, with Neoralİ (cyclosporine, USP ), Simulectİ (basiliximab), myforticİ (mycophenolic acid) and Sandimmuneİ (cyclosporine, USP). Our focus is to develop meaningful therapeutic advances that improve quality of life and enhance the long-term success of transplantation. In partnership with the transplant community, 30 leading research institutions and with more than 300 scientists and clinicians dedicated to transplant research, we maintain the broadest pipeline in the field with two compounds in clinical trials and more than a dozen projects in pre-clinical development.

At Novartis Oncology, we strive to provide a broad range of innovative therapies and practical solutions that change the way patients live with cancer. Every day, around the world we are exploring and pioneering new treatments that are likely to transform the way cancer is treated.

Silver

Centocor Ortho Biotech Services, LLC. is a new company encompassing scientific and business functions supporting both Centocor, Inc. and Ortho Biotech Products, L.P. that will offer customer centric solutions through a single point of contact. With a strong portfolio of existing treatments and the promise of innovative therapies currently in development, we will work with our partner companies to transform lives today and for generations to come.

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADEİ (bortezomib) for Injection, a novel cancer product, and has a robust clinical development pipeline of product candidates. The Company's research, development and commercialization activities are focused in two therapeutic areas: oncology and inflammation. By applying its knowledge of the human genome, understanding of disease mechanisms and industrialized drug discovery platform, Millennium is developing an exciting pipeline of innovative product candidates.

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com.

Bronze

For more than 40 years, Byram Healthcare has been providing a broad range of medical supplies to patients in the home.  The company fills more than one million patient orders annually, serves 300,000 patients and through its various managed care contractual relationships, reaches 115 million covered lives.  Byram operates five distribution facilities and four customer call centers along with six sales and service centers - all of which are strategically located throughout the U.S.  Byram is recognized for its broad clinical specialty support programs that span the diabetes, wound care, ostomy, urological, incontinence and enteral nutrition areas.  These innovative and complimentary clinical solutions allow patients, payors and healthcare professionals to better address the challenges of today's dynamic market by removing barriers to care, improving access, enhancing quality and reducing costs.

Founded in 1855, The Children's Hospital of Philadelphia is the birthplace of pediatric medicine in America. Throughout its history, a passionate spirit of innovation has driven this renowned institution to pursue scientific discovery, establish the highest standards of pediatric care and train future leaders in pediatrics. For a century and a half, Children's Hospital has served as a haven of hope for children and families worldwide.

Coram Specialty Infusion Services is a leader in providing home infusion therapies and services to pre- and post-transplant patients. Coram's experience supporting alternate site care throughout the transplant process includes the care of autologous and allogeneic blood cell transplant, cord blood transplant, and all major solid organ transplant recipients. Coram has supported the care management of blood cell and organ transplant patients since 1991, providing therapies and services to more than 58,000 transplant patients to date and now totaling approximately 3,500 patients annually. Coram's goals are to assure continuity of care, measure and manage treatment outcomes, and help contain total transplant costs.

The National Marrow Donor Program facilitates stem cell transplants for patients with life-threatening blood diseases by recruiting donors, maintaining a Registry of nearly four million volunteer donors from all over the world, coordinating the donation of stem cells and offering patient services - while also conducting research to further the field of unrelated marrow transplantation.

Individual Event Partners and Supporters

Bronze

Abbott discovers, develops, manufactures, and markets products and services that span the continuum of care - from prevention and diagnosis, to treatment and cure. Abbott casts a keen focus on areas with the greatest unmet medical need, such as oncology, infectious diseases, diabetes, obesity, immunology, neuroscience and cardiovascular disease.

Genentech, the founder of the biotechnology industry, is a company with a quarter-century track record of delivering on the promise of biotechnology. Today, Genentech is among the world's leading biotech companies, with multiple protein-based products on the market for serious or life-threatening medical conditions and over 30 projects in the pipeline. With its strength in all areas of the drug development process - from research and development to manufacturing and commercialization. Genentech continues to transform the possibilities of biotechnology into improved realities for patients.

One of the world's foremost biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. With many established products and services helping patients in more than 80 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences to address a range of unmet medical needs. The company's products and services are focused on rare inherited disorders, kidney disease, orthopedics, transplant and immune disease, cancer, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial research and development program focused on genetic diseases, immune system disorders, heart disease, and cancer.

Novo Nordisk is a healthcare company and a world leader in diabetes care. We offer a broad diabetes product portfolio, including innovative insulin delivery systems. In addition, Novo Nordisk has a leading position within such therapeutic areas as hemostasis management, growth hormone therapy and hormone therapy for women.

Novo Nordisk employs approximately 26,000 full-time employees in 79 countries, and we reach out to 180 countries around the world with our products and programs. We operate manufacturing facilities in six nations, including the United States.

Roche Laboratories is a leading research-intensive pharmaceutical company that discovers, develops, manufactures and markets numerous important prescription drugs that improve, prolong and save the lives of patients. Among the company's areas of therapeutic interests are virology, infectious diseases, cardiology, dermatology, obesity, and transplantation. Roche Laboratories, in Nutley, N.J., and its parent organization Hoffmann-La Roche, are members of the Basel, Switzerland-based Roche Group, a global leader in health care with principal businesses in pharmaceuticals, diagnostics, vitamins, and fragrances and flavors. Last year Roche invested more than 1.8 billion dollars in pharmaceutical research and development to remain at the forefront of biomedical research and knowledge